Rare Disease Discovery: B3 for NMD - Bench to Bedside and Back- Transformative discoveries leading to improved care in Neuromuscular Disease 

Status: Ongoing, Open for Recruitment

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD) 

Status: Ongoing, Recruitment closed 

A Phase II Randomized, Placebo-Controlled, Double-Blinded, Multi-Centre Clinical Trial of Pimozide in Patients with Amyotrophic Lateral Sclerosis 

Status: Ongoing, Open for Recruitment

A Phase 2a, Multicentre, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients 

Status: Ongoing, Open for Recruitment 

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 24-Week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetic Patients with Peripheral Neuropathy 

Status: Ongoing, Open for Recruitment

A Pilot, Open-label, Dose-response Study Investigating the Effect of Low-dose Celecoxib on SMN2 in Patients with Spinal Muscular Atrophy CEL20150 

Status:  TBA

Enhanced CARE for RARE Genetic Diseases in Canada (C4R) 

Status: Open for Recruitment

Factors Influencing Pursuit of Medical Assistance in Dying (MAID) in ALS Patients 

Status:  Ongoing, Open for Recruitment

Understanding Palliative Care and End of Life Needs in the ALS Population: The First Step to Improving Patient and Caregiver Quality of Life

Status: Ongoing, Open for Recruitment

A Prospective, Multi-center, Observational Study of the Safety, Tolerability, and Effectiveness of SPINRAZA in Adult Patients with Spinal Muscular Atrophy

Status: Ongoing, Open for Recruitment

To participate in our clinical trials, please contact Maria Duff ( or Sergio Guber (

Contact us:

Phone Number: 613-761-4324

Fax: 613-761-5403

1053 Carling Avenue, Ottawa, ON, K1Y4E9

  • Facebook
  • Twitter